474289-84-4Relevant academic research and scientific papers
Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
Gellibert,Fouchet,Nguyen,Wang,Krysa,de Gouville,Huet,Dodic
, p. 2277 - 2281 (2009)
Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid).
